Latest market price
43.66
+0.75+1.75%
OverviewShort InterestFilings
SRRKQT60Scholar Rock Holding Corporation·NASDAQ
43.66+1.75%
TA
Loading chart...
Signal & projected range
Descending channel — reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
COGT+4.51%$31.07PTCT+12.26%$68.34MANE+3.27%$133.76CGON+5.75%$65.53ERAS+3.91%$14.60MIRM+2.31%$87.72CRSP+0.30%$50.14IMVT+2.47%$29.11
Snapshot
Index—P/E—EPS (ttm)-3.31Insider Own47.06%Shs Outstand121.78MPerf Week2.88%
Market Cap5.23BForward P/E—EPS next Y-2.61Insider Trans0.48%Shs Float100.76MPerf Month-8.33%
Enterprise Value4.93BPEG—EPS next Q-0.85Short Float22.01%Perf Quarter-10.21%
Income-409.00MP/S—EPS this Y—Short Ratio14.11Perf Half Y-7.68%
Sales0.00P/B20.57EPS next Y—ROA-78.04%Short Interest22.18MPerf YTD-2.59%
Book/sh2.09P/C10.62EPS next 5Y—ROE-160.19%52W High61.76 -29.31%Perf Year46.10%
Cash/sh4.04P/FCF—EPS past 3/5Y—ROIC-88.80%52W Low27.07 61.29%Perf 3Y304.43%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility4.04% 4.27%Perf 5Y61.92%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.90Perf 10Y—
Dividend Ex-Date—Quick Ratio7.02Sales Y/Y TTM—Profit Margin0.00%RSI (14)45.31Recom2.00
Dividend Gr. 3/5Y—Current Ratio7.02EPS Q/Q14.29%SMA202.39%Beta0.77Target Price71.30
Payout0.00%Debt/Eq0.78Sales Q/Q—SMA50-10.97%Rel Volume0.55Prev Close42.91
Employees289LT Debt/Eq0.78EarningsNov 10SMA200-10.95%Avg Volume1.69MPrice43.66
IPO DateMay 25, 2018Option/ShortYes / YesEPS/Sales Surpr.0.06% —Net Debt/EBITDA—Volume932,042Change1.75%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-24-26ReiteratedTruist SecuritiesBuy$76 → $77
Sep-21-26ReiteratedCantor Fitzgerald$70
Sep-15-26ReiteratedWedbushOutperform$64 → $70
Sep-15-26ReiteratedHC Wainwright & Co.Buy$65 → $70
Sep-15-26DowngradeBarclaysOverweight → Equal Weight$58
Sep-15-26ReiteratedPiper SandlerOverweight$58 → $75
Sep-15-26ReiteratedEvercore ISI GroupOutperform$72
Sep-14-26ReiteratedRaymond JamesStrong Buy$53 → $72
Sep-14-26ReiteratedWedbushOutperform$64 → $70
Sep-14-26ReiteratedBMO CapitalOutperform$76 → $84
Latest News· Times ET
Oct-30-26
Oct-30-2605:13AM
Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet HopesYahoo
Oct-23-26
Oct-23-2604:56AM
Scholar Rock Receives FDA's Priority Review Voucher For IsembyldBenzinga
Oct-20-26
Oct-20-2608:00AM
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026gurufocus.com
Oct-16-26
Oct-16-2604:15PM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Oct-15-26
Oct-15-2609:20PM
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)Yahoo
Oct-08-26
Oct-08-2608:00AM
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)Yahoo
Oct-07-26
Oct-07-2608:21AM
Scholar Rock (NASDAQ:SRRK) Stock Falls 5.1% – Here’s What Happeneddefenseworld.net
Oct-05-26
Oct-05-2604:41AM
Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga
Sep-30-26
Sep-30-2609:56AM
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firmprnewswire.com
Sep-28-26
Sep-28-2606:44AM
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early ApprovalsYahoo
Sep-24-26
Sep-24-2607:56AM
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77Benzinga
Sep-21-26
Sep-21-2612:00PM
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
Sep-18-26
Sep-18-2603:13AM
Scholar Rock Holding Corporation $SRRK Shares Bought by Engineers Gate Manager LPdefenseworld.net
Sep-15-26
Sep-15-2607:16PM
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst RevisionsYahoo
03:11PM
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Playseekingalpha.com
Company

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A9720823—————
Gross Profit-97-208-2-3—————
Selling, General and Administrative Excl. Other1991766849—————
Research and Development207208183119—————
Other Operating Expense-97-208-10—————
Operating Income-407-385-252-171—————
Interest Expense11770—————
Unusual Expense
—————————
Non-Operating Income (Expense)914136—————
Net Income Before Taxes-409-378-246-166—————
Income Taxes
0000—————
Consolidated Net Income-409-378-246-166—————
Net Income From Continuing Operations-409-378-246-166—————
Net Income-409-378-246-166—————
EPS (Recurring)-3.31-3.29-2.47-1.99—————
EPS (Basic, Before Extraordinaries)-3.31-3.29-2.47-1.99—————
EPS (Diluted)-3.31-3.29-2.47-1.99—————
EBITDA-396-369-238-163—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding13111510076—————
Market Capitalization5,7195,0664,3221,429—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$64.86$54.42$43.98$33.54$23.10● Close Price0.00M3.00M6.00M9.00M12.00MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
AKKARAJU SRINIVASDirectorOct 26 '26Buy41.59146,9706,112,4826,380,517Oct 27
AKKARAJU SRINIVASDirectorOct 23 '26Buy41.32142,5005,887,4406,331,529Oct 27
FLIER JEFFREY S.DirectorJul 01 '26Sale53.883,053164,49027,856Jul 06
Peng KatieDirectorJul 01 '26Sale53.885,446293,40534,301Jul 06
Gilman MichaelDirectorJul 01 '26Sale53.882,544137,05859,511Jul 06
Burow KristinaDirectorJul 01 '26Sale53.743,053164,064114,657Jul 06
Reed JoshuaDirectorJul 01 '26Sale53.743,053164,06819,518Jul 06
Burow KristinaDirectorApr 23 '26Option Exercise9.1389,800820,324110,871Apr 24
Woods KeithChief Operating OfficerApr 16 '26Sale49.5710,220506,651620,055Apr 20
Vaishnaw AkshayPresident of R&DApr 16 '26Sale49.5712,246607,089630,542Apr 20
Sinha VikasChief Financial OfficerApr 16 '26Sale49.5710,410516,071619,856Apr 20
Hallal DavidChief Executive OfficerApr 16 '26Sale49.5730,6151,517,7231,639,034Apr 20
Qatanani MoCHIEF SCIENTIFIC OFFICERFeb 23 '26Sale47.078,484399,35198,445Feb 25
Marantz Jing L.CHIEF MEDICAL OFFICERFeb 17 '26Sale46.534,157193,418126,012Feb 19
Ho JunlinGENERAL COUNSELFeb 17 '26Sale46.539,580445,740241,545Feb 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.